je.st
news
Triferic: The Kill Shot For AMAG Pharmaceuticals' Feraheme
2015-01-28 14:36:45| Biotech - Topix.net
Cruise-1/-2 Phase III trials met all primary and secondary endpoints with safety equivalent to placebo resulting in a highly differentiated and disruptive new entry into CKD market. AMAG Pharmaceuticals has issued puzzling guidance for Feraheme in 2015: Sales are projected to grow from ~$86 Million in 2014 to a range of approximately $86-102 MM in 2015 .
Tags: shot
kill
pharmaceuticals
amag
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||